CLINICAL TRIAL SUMMARY

MDACC Study No:2009-0057 (clinicaltrials.gov NCT No: NCT00958256)
Title:Phase II study of bortezomib in combination with cyclophosphamide and rituximab for relapsed/refractory mantle cell lymphoma
Principal Investigator:Jorge Romaguera
Treatment Agent:Bortezomib
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if bortezomib when given
in combination with cyclophosphamide and rituximab can help to control mantle
cell lymphoma. The safety of this drug combination will also continue to be
studied.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:Bortezomib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:NA
Supported By:Millennium
Return Visit:Patients will receive a cycle of chemotherapy every 21 days up to 8 cycles.
Home Care:NA


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Romaguera
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults